Scalper1 News
Big pharma Eli Lilly (LLY) said Monday that it’s stopping development of its cholesterol drug evacetrapib after a review of its phase-three trial data showed it wasn’t having much of an effect. Lilly has been conducting a giant study of the cardiovascular effects of evacetrapib, which isn’t due for completion until next year. An independent data-monitoring committee, however, reviewed the results so far and recommended stopping now on account of Scalper1 News
Scalper1 News